Cover Image

HARDBACK
$69.95



View/Hide Left Panel

TABLE 4-4 Outcome Measures for Falls: Summary of Evidence from Randomized Trials with Vitamin D and Calcium

Reference; Study Duration; Outcome

N

Vitamin D Dose

Calcium Dose

Serum 25OHD level (nmol/L)

Falls

Fallers

RR/OR (95% CI)/(p-value)

Baseline

Achieved

Studies using oral doses

Bischoff et al., 2003a 12 weeks follow-up (primary analysis)

122

Placebo

1,200 mg/d

29.0 (23.0–25.0)

28.0 (24.5–41.5)

0.68 (0.30–1.54)

 

800 IU/d

1,200 mg/d

30.8 (23.0–55.0)

65.5 (49.8–82.8)

0.70 (0.30–1.50)

Bischoff-Ferrari et al., 2006b 3-year trial (secondary outcome of primary analysis)

Women:

Women:

Women:

Women:

Women:

Women:

Women:

246

Placebo

Placebo

63.0 (± 30.3)

68.0 (± 32.5)

0.44 (0.21–0.90)

 

700 IU/d

500 mg/d

70.0 (± 33.0)

104.0 (± 41.8)

 

 

 

Men:

Men:

Men:

Men:

Men:

Men:

Men:

199

Placebo

Placebo

83.0 (± 33.5)

76.5 (± 27.3)

0.84 (0.42–1.66)

 

700 IU/d

500 mg/d

82.0 (± 37.5)

110.0 (± 34.0)

 

 

 

Bischoff-Ferrari et al., 2010 12-month trial (primary outcome)

173

800 IU/d

500 mg/d

30.8 (± 19.3)

88.5 (± 25.3)

28 (−4.0–68.0

 

2,000 IU/d

500 mg/d

33.0 (± 20.3)

111.8 (± 26.0)

 

 

 

Broe et al., 2007 5-month study period (secondary analysis)

124

Placebo

 

53.0 (± 28.5)

 

 

 

 

200 IU/d

None

44.5 (± 23.0)

 

 

 

1.10 (0.49–2.50)

 

400 IU/d

None

51.8 (± 29.0)

 

 

 

1.05 (0.48–2.28)

 

600 IU/d

None

41.3 (± 18.5)

 

 

 

1.21 (0.55–2.61)

 

800 IU/d

None

53.5 (± 23.0)

 

 

 

0.28 (0.10–0.75)b

Burleigh et al., 2007a 30 days (primary outcome)

203

Placebo

1,200 mg/d

24.7 (± 10.0)

0.82 (0.59–1.16)

 

800 IU/d

1,200 mg/d

21.7 (± 7.1)

 

 

 



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement